Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 30 March, 2009
Dosage: TABLET;ORAL
14
Norway
14
Japan
12
European Union
10
United States
10
Israel
9
Lithuania
8
Spain
8
Russia
7
Hong Kong
7
China
7
Portugal
6
Denmark
6
Cyprus
6
Slovenia
5
Czech Republic
5
Poland
5
Slovakia
3
Canada
3
Korea, Republic of
3
Mexico
3
Luxembourg
2
United Kingdom
2
Taiwan
1
Brazil
1
New Zealand
1
Australia
1
South Africa
1
Hungary
Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Dosage: SOLUTION;INTRAVENOUS
8
United States
2
Korea, Republic of
2
China
2
Japan
2
Australia
2
European Union
1
Canada
Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
New Patient Population (NPP) | Dec 20, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 2024-02-26
Market Authorisation Date: 25 February, 2015
Dosage: POWDER;INTRAVENOUS
6
United States
2
Poland
2
Japan
2
ME
2
France
2
Australia
1
Spain
1
Austria
1
Hong Kong
1
Turkey
1
Denmark
1
AP
1
Czech Republic
1
Germany
1
China
1
Yugoslavia
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Estonia
1
Argentina
1
EA
1
OA
1
Norway
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
Costa Rica
1
Ecuador
1
Algeria
1
Bulgaria
1
South Africa
1
Slovakia
1
Slovenia
1
Hungary
1
European Union
Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma; Treatment of a...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(1 year, 3 months from now) | |
US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(13 years from now) | |
US11098015 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
US10039757 | EXELIXIS INC | C-Met modulator pharmaceutical compositions |
Jul, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Dosage: TABLET;ORAL
67
United States
22
Japan
14
Australia
13
European Union
12
Korea, Republic of
9
Taiwan
8
Spain
7
China
7
New Zealand
6
Hong Kong
6
Denmark
6
Canada
5
Poland
5
Croatia
5
Slovenia
4
EA
4
Portugal
3
Austria
3
Singapore
3
Argentina
3
Cyprus
3
Israel
3
Mexico
2
Brazil
2
South Africa
2
Hungary
1
RS
1
Russia
1
Morocco
1
San Marino
1
Netherlands
1
Lithuania
1
Luxembourg
Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; Long-term treatment of adults with gaucher disease type 1 who ...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10888544 | GENZYME CORP | Methods for treating Gaucher disease |
Dec, 2038
(15 years from now) |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
Market Authorisation Date: 19 August, 2014
Dosage: CAPSULE;ORAL
4
United States
1
Korea, Republic of
1
China
1
Russia
1
Israel
1
Canada
1
Brazil
1
Singapore
1
Colombia
1
Mexico
1
Japan
1
Australia
1
European Union
Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11236328 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 30, 2023 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
Market Authorisation Date: 30 March, 2016
Dosage: SOLUTION;INTRAVENOUS
6
United States
4
Korea, Republic of
2
China
1
Italy
1
Spain
1
Russia
1
Hong Kong
1
Brazil
1
Israel
1
Canada
1
Singapore
1
India
1
Mexico
1
Japan
1
Australia
1
Denmark
1
European Union
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 2 months from now) |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 26 October, 2004
Dosage: TABLET, CHEWABLE;ORAL
8
United States
5
Denmark
5
European Union
4
Spain
4
Poland
4
Cyprus
4
Portugal
4
Slovenia
3
Canada
3
EA
3
Japan
3
Australia
2
Austria
2
Germany
2
China
2
Brazil
2
Norway
2
Korea, Republic of
2
South Africa
2
Hungary
1
IB
1
Hong Kong
1
Iceland
1
Czech Republic
1
Singapore
1
Argentina
1
New Zealand
1
Peru
1
Israel
1
Taiwan
1
Mexico
1
Finland
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2024
(10 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11504365 | AVEO PHARMS | NA |
Nov, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-03-10
Market Authorisation Date: 10 March, 2021
Dosage: CAPSULE;ORAL
7
United States
6
Japan
3
European Union
2
Austria
2
Germany
2
Brazil
2
Canada
2
Norway
2
Australia
1
Spain
1
Hong Kong
1
Denmark
1
Poland
1
China
1
Russia
1
EA
1
New Zealand
1
Korea, Republic of
1
Belgium
1
Chile
1
Israel
1
Taiwan
1
Mexico
1
Netherlands
1
South Africa
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10449173 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Dosage: GEL;TRANSDERMAL
5
United States
4
Mexico
2
Spain
2
Canada
2
Japan
2
European Union
1
Korea, Republic of
1
Germany
1
Russia
1
China
1
Brazil
1
South Africa
1
Australia
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 2024-12-23
Market Authorisation Date: 23 December, 2020
Dosage: TABLET;ORAL
8
United States
3
Japan
3
Korea, Republic of
2
Dominican Republic
2
China
2
Costa Rica
1
Spain
1
Austria
1
Hong Kong
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Morocco
1
Argentina
1
EA
1
ME
1
Nicaragua
1
New Zealand
1
Honduras
1
Croatia
1
Cyprus
1
Peru
1
Chile
1
Israel
1
Portugal
1
El Salvador
1
Taiwan
1
Georgia
1
Mexico
1
Australia
1
Ecuador
1
South Africa
1
Colombia
1
Tunisia
1
Slovenia
1
European Union
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) | |
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
Market Authorisation Date: 30 January, 2015
Dosage: TABLET;ORAL
7
United States
3
Canada
3
European Union
2
China
2
Japan
2
Korea, Republic of
2
Mexico
1
Spain
1
Hong Kong
1
Philippines
1
Turkey
1
Denmark
1
RS
1
Poland
1
EA
1
New Zealand
1
Croatia
1
Cyprus
1
Israel
1
Chile
1
Portugal
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucou...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 2021-12-14
Market Authorisation Date: 14 December, 2017
Dosage: SOLUTION;NASAL
Treatment: Method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(4 years from now) | |
US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Apr 28, 2024 |
New Patient Population (NPP) | Nov 19, 2024 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 25 July, 2013
Dosage: SOLUTION;INTRAVENOUS
24
United States
6
European Union
5
Korea, Republic of
3
Spain
3
Hong Kong
3
Denmark
3
Canada
3
Cyprus
3
Portugal
2
Germany
2
China
2
Brazil
2
Norway
2
Japan
2
Jordan
2
Australia
2
Slovenia
1
Uruguay
1
Austria
1
Malaysia
1
Poland
1
Russia
1
Argentina
1
New Zealand
1
Peru
1
Israel
1
Taiwan
1
Mexico
1
South Africa
1
Lithuania
1
Saudi Arabia
1
Hungary
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advan...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(11 years from now) | |
US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(13 years from now) |
Drugs and Companies using AXITINIB ingredient
Market Authorisation Date: 27 January, 2012
Dosage: TABLET;ORAL
14
United States
5
Japan
4
European Union
2
Spain
2
Poland
2
China
2
Canada
2
Singapore
2
Korea, Republic of
2
Portugal
2
Taiwan
2
Mexico
2
Australia
2
Slovenia
2
Hungary
1
Hong Kong
1
Philippines
1
Malaysia
1
Turkey
1
Denmark
1
Russia
1
Brazil
1
EA
1
New Zealand
1
Cyprus
1
Israel
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 10 months from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2014
Dosage: TABLET;ORAL
45
United States
14
Japan
11
European Union
10
China
9
Argentina
9
Taiwan
8
Canada
8
EA
8
Australia
8
South Africa
7
Ukraine
6
Spain
5
Norway
5
New Zealand
5
Korea, Republic of
5
Ecuador
4
Malaysia
4
Iceland
4
Yugoslavia
4
Brazil
4
Israel
4
Mexico
4
Costa Rica
3
Denmark
3
Poland
3
Croatia
3
Cyprus
3
Peru
3
Portugal
3
Slovenia
2
RS
2
Singapore
2
ME
2
Hungary
1
Uruguay
1
Panama
1
Hong Kong
1
Nicaragua
1
Honduras
1
Guatemala
1
Chile
1
El Salvador
1
Netherlands
1
Colombia
1
Lithuania
1
Luxembourg
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 10 months from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 20 September, 2016
Dosage: TABLET, EXTENDED RELEASE;ORAL
45
United States
14
Japan
11
European Union
10
China
9
Argentina
9
Taiwan
8
Canada
8
EA
8
Australia
8
South Africa
7
Ukraine
6
Spain
5
Norway
5
New Zealand
5
Korea, Republic of
5
Ecuador
4
Malaysia
4
Iceland
4
Yugoslavia
4
Brazil
4
Israel
4
Mexico
4
Costa Rica
3
Denmark
3
Poland
3
Croatia
3
Cyprus
3
Peru
3
Portugal
3
Slovenia
2
RS
2
Singapore
2
ME
2
Hungary
1
Uruguay
1
Panama
1
Hong Kong
1
Nicaragua
1
Honduras
1
Guatemala
1
Chile
1
El Salvador
1
Netherlands
1
Colombia
1
Lithuania
1
Luxembourg
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 ...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(7 years from now) | |
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 10 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
Market Authorisation Date: 29 March, 2013
Dosage: TABLET;ORAL
51
United States
16
Japan
12
China
12
European Union
11
Australia
10
Argentina
10
Taiwan
9
Canada
9
EA
8
Ukraine
8
South Africa
7
Spain
7
New Zealand
6
Korea, Republic of
6
Ecuador
5
Malaysia
5
Brazil
5
Norway
5
Israel
5
Mexico
5
Costa Rica
4
Iceland
4
Denmark
4
Poland
4
Yugoslavia
4
Singapore
4
Croatia
4
Cyprus
4
Peru
4
Portugal
4
Slovenia
3
RS
3
ME
3
Hungary
2
Uruguay
2
Hong Kong
2
Nicaragua
2
Guatemala
2
Chile
2
Colombia
2
Lithuania
1
Panama
1
Honduras
1
San Marino
1
El Salvador
1
Jordan
1
Netherlands
1
Luxembourg
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) | |
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Aug 18, 2024 |
M (M) | Feb 24, 2025 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
Market Authorisation Date: 01 August, 2014
Dosage: TABLET;ORAL
7
United States
3
Canada
3
European Union
2
China
2
Japan
2
Korea, Republic of
2
Mexico
1
Spain
1
Hong Kong
1
Philippines
1
Turkey
1
Denmark
1
RS
1
Poland
1
EA
1
New Zealand
1
Croatia
1
Cyprus
1
Israel
1
Chile
1
Portugal
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(4 years from now) | |
US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 2025-08-23
Market Authorisation Date: 23 August, 2021
Dosage: SOLUTION;INTRAVENOUS
32
United States
3
Canada
3
Japan
3
Korea, Republic of
2
Malaysia
2
Russia
2
China
2
New Zealand
2
Israel
2
Mexico
2
Australia
2
South Africa
2
European Union
1
Spain
1
Hong Kong
1
Denmark
1
Poland
1
Brazil
1
Cyprus
1
Portugal
1
Lithuania
1
Slovenia
1
Hungary
Treatment: Method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney d...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8815301 | PHARMACOSMOS AS | Stable iron oligosaccharide compound |
Aug, 2029
(6 years from now) |
Drugs and Companies using FERRIC DERISOMALTOSE ingredient
Market Authorisation Date: 16 January, 2020
Dosage: SOLUTION;INTRAVENOUS
8
United States
3
Denmark
3
China
3
European Union
2
Spain
2
RS
2
Poland
2
Croatia
2
Portugal
2
Lithuania
2
Slovenia
2
Hungary
1
Hong Kong
1
Philippines
1
Brazil
1
Canada
1
Ukraine
1
EA
1
Japan
1
New Zealand
1
Korea, Republic of
1
Cyprus
1
Mexico
1
Australia
1
South Africa
Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for th...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(5 months from now) | |
US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(5 months from now) | |
US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(5 years from now) | |
US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Mar 25, 2024 |
Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 28 June, 2012
Dosage: TABLET, EXTENDED RELEASE;ORAL
12
United States
9
Japan
4
European Union
3
Spain
3
Denmark
3
Poland
3
China
3
Canada
3
Portugal
3
Slovenia
2
Russia
2
Brazil
2
Norway
2
Croatia
2
Korea, Republic of
2
Cyprus
2
Israel
2
Mexico
2
Australia
2
South Africa
2
Hungary
1
Austria
1
Hong Kong
1
Germany
1
New Zealand
1
Taiwan
1
Netherlands
1
Lithuania
1
Luxembourg
Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; Treatment of unresec...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(3 months ago) | |
US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(5 years from now) |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Dosage: TABLET;ORAL
12
United States
7
European Union
5
Japan
5
Korea, Republic of
4
Peru
3
Spain
3
Hong Kong
3
Denmark
3
China
3
Canada
3
Cyprus
3
Portugal
3
Australia
3
Slovenia
2
Malaysia
2
Poland
2
Brazil
2
Ukraine
2
Singapore
2
Morocco
2
Argentina
2
Norway
2
New Zealand
2
Croatia
2
Honduras
2
Guatemala
2
Israel
2
Taiwan
2
Mexico
2
Cuba
2
South Africa
1
Uruguay
1
Austria
1
Dominican Republic
1
Germany
1
Russia
1
Costa Rica
1
Ecuador
1
Tunisia
Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7300674 | DIALYSIS SUPS | Sterile low bicarbonate dialysis concentrate solutions |
Mar, 2023
(2 months ago) |
Drugs and Companies using MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient
Market Authorisation Date: 26 July, 2006
Dosage: SOLUTION;INJECTION
3
United States
2
Canada
1
Australia
1
European Union
Treatment: Treatment of anemia due to chronic kidney disease
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(11 months from now) | |
US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(11 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) | |
US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
Market Authorisation Date: 27 March, 2012
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
21
United States
6
Japan
3
Korea, Republic of
3
European Union
2
China
2
Brazil
2
Canada
2
Ukraine
2
Singapore
2
EA
2
Norway
2
New Zealand
2
Mexico
2
Australia
2
Costa Rica
2
South Africa
1
Spain
1
Hong Kong
1
Austria
1
Iceland
1
Denmark
1
AP
1
Poland
1
Germany
1
Yugoslavia
1
Morocco
1
OA
1
ME
1
Croatia
1
Cyprus
1
Israel
1
Portugal
1
Georgia
1
Slovenia
Treatment: Dose modification for renal impairment
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(4 years from now) |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Dosage: TABLET, EXTENDED RELEASE;ORAL
5
United States
Treatment: Treating secondary hyperparathyroidism in stage 3/4 chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversup...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11154509 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
US9925147 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
11
United States
6
Korea, Republic of
5
European Union
4
Hong Kong
4
Japan
3
Spain
3
Portugal
3
Denmark
2
Poland
2
China
2
Cyprus
2
Canada
2
Slovenia
1
Norway
Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 16, 2024 |
Generating Antibiotic Incentives Now (GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 2028-07-16
Market Authorisation Date: 16 July, 2019
Dosage: POWDER;INTRAVENOUS
4
United States
3
Japan
3
Lithuania
2
Spain
2
Hong Kong
2
Denmark
2
RS
2
Poland
2
China
2
Croatia
2
Korea, Republic of
2
Cyprus
2
Portugal
2
Ecuador
2
Netherlands
2
Slovenia
2
Hungary
2
European Union
1
Dominican Republic
1
Malaysia
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Norway
1
ME
1
Nicaragua
1
Honduras
1
New Zealand
1
Israel
1
Mexico
1
Australia
1
Costa Rica
1
South Africa
1
Colombia
1
Luxembourg
Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage...
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) | |
US11278547 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Dosage: TABLET;ORAL
5
United States